BioInvent is focused on developing novel immuno-modulatory antibodies for cancer therapy. BioInvent’s innovative antibodies may significantly improve the efficacy of currently available immuno-modulatory checkpoint inhibitor therapies and/or activate anti-cancer immunity in currently non-responding patients and cancer types.

 

1L/2L: First/second line treatment
CTCL: Cutaneous T-cell Lymphoma
NHL: Non-Hodgkin’s Lymphoma
FL: Follicular Lymphoma
MCL: Mantle Cell Lymphoma
MZL: Marginal Zone Lymphoma 
NSCLC: Non-small cell lung cancer

Our publications

BioInvent's cutting-edge research is acknowledged through high quality scientific publications. The company's scientists have a documented track-record of being accepted for publication in high impact-factor publications.
Read more
Read more

BioInventEvents

Our events are hosted globally and online
Here are up and coming events both in person and online.

See all of our events here.

Lorem ipsum dolor sit amet, consectetur adipiscing elit

BioInventInvestor

BioInvent is in a very attractive position with several value drivers

All pharmaceutical development is associated with risk. BioInvent manages these risks by a stringent portfolio management, a diversified approach to drug candidates and mechanisms of action, and by targeting a very attractive space in the pharmaceutical landscape. Partnerships within the big pharma community, solid ownership and a strong cash position give BioInvent a solid platform to continue its transformation.

Read more